Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseLong-acting beta2-agonists for chronic obstructive pulmonary diseaseTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseA rational approach to single, dual and triple therapy in COPDCan the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Impact of bronchodilator therapy on exercise tolerance in COPD.Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesEffect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary diseaseRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.Determinants of spirometry use and accuracy of COPD diagnosis in primary careInhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.The role of bronchodilator treatment in the prevention of exacerbations of COPD.Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study.The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPDInhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis.Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis.The role of nebulized therapy in the management of COPD: evidence and recommendations.No room to breathe: the importance of lung hyperinflation in COPD.Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD.COPD updates: what's new in pathophysiology and management?Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.Optimizing bronchodilation in the prevention of COPD exacerbationsComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology.Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? No.The safety and efficacy of arformoterol and formoterol in COPD.Réfutation: Faut-il éviter les β-agonistes dans les cas de bronchopneumopathies chroniques obstructives modérées et graves?: NON.Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.Medication use patterns associated with spirometry in diagnosing COPD.A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructiEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
P2860
Q22305858-98E0F063-6756-48C0-8BBB-AE3281CE1A36Q24197467-AFC27147-8B48-4104-A786-7CC7F035FAA4Q24200476-F4D2BF98-8812-4E15-A8CE-AEFF781A39E1Q26776477-9C47979B-0F68-4064-91B5-1FF089E81FCFQ28391808-ABC04C47-5722-4781-BF5A-3E37B78BEC75Q33831434-7E3DF3E5-BEE2-4633-B147-A2898042A268Q34065963-ADA0AA85-9B3D-43CA-8F92-81358A9F57A2Q34198955-D8CC1408-9FEE-4B1D-8341-259FD4F6F671Q34554816-16D8F90D-3A12-496E-A07A-04EEA12B9650Q34957303-227BFBD1-59E5-416A-AB2D-9C6152BB30F4Q35527052-461349E4-759A-462B-A28A-AD9F4763033CQ35778149-C2E44284-2D0D-41A7-B659-BAC818328319Q35838660-256CB30B-BE26-41F3-BF22-2F61A9EA2289Q36438669-D4A84E22-0FF0-4328-A068-67E8F4A79DE2Q36695412-0BB94FD8-461D-46E7-B23A-E52FE89996B3Q36908742-0D0A478E-A33D-4BED-8889-8C548F5005C7Q37017315-A5D9A250-FF41-4F1C-AEBB-AB69520BFF5EQ37085936-754988DD-8C2D-4685-B7EC-A003DC0B750AQ37603579-E3481D12-E8D8-4870-BFC9-ED600701336DQ37748948-72BC10CA-B50D-4004-938F-67ACB89036D2Q37804908-1F79D382-2562-47FF-B9DA-1C3329E17B8DQ37864538-F62CB2A0-49E1-44D5-8291-651A92E732A1Q37980189-CD6F82E9-58CA-41FB-BBA1-4D1FDA907D92Q38083537-3E1C4EE4-0573-4E63-B04D-65F8C49A08F4Q38083660-08B272E5-8BE7-46A5-8118-74652DA0EA9FQ38130515-05AC1917-879E-4712-85B9-E4ADBFE637DEQ38308933-0182E06C-80E6-450C-9739-6E9E88B62AF0Q38604644-5630E1C4-FB0C-4E16-AE70-1864EF8B100FQ39386571-36EF7C3D-E507-467B-8007-C5E2E34A58C5Q39399389-1E5D5A59-074F-4BA9-B3FB-E97A798853EFQ40179319-625A75EC-5F85-4D8D-9B9B-BCE635126A02Q41954093-8EA5D0C9-7736-41DD-A51F-344D804A32E1Q43137231-F4D72B70-BE19-4E51-91D4-9FD0074C3CD4Q45762530-FEC5FB77-7ED2-43A8-86AE-3A7768BE9899Q45917632-550382A8-635C-4EE4-814F-E276CBF5B658Q46057466-B03BF646-7C58-4E61-8EE0-E7249A1D21E7Q46452143-0979681A-9F1C-47A3-B792-94D560A369E5Q46568144-00A5922C-9A9B-4285-8EC8-0046B5131EC6Q48487432-31795A76-709B-4823-90EE-031AE541C5E8
P2860
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@ast
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@en
type
label
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@ast
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@en
prefLabel
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@ast
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@en
P2093
P2860
P356
P1433
P1476
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
@en
P2093
P2860
P304
P356
10.1136/THX.2004.033266
P407
P577
2006-02-01T00:00:00Z